Displaying drugs 1 - 25 of 111 in total
Deferoxamine
Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
Approved
Investigational
Matched Description: … It forms iron complexes and is used as a chelating agent, particularly in the mesylate form. …
Matched Salts name: … Deferoxamine mesylate …
Matched Products: … Deferoxamine Mesylate ... Deferoxamine mesylate ... Deferoxamine Mesylate for Injection …
Matched Salts name: … Deferoxamine mesylate …
Matched Products: … Deferoxamine Mesylate ... Deferoxamine mesylate ... Deferoxamine Mesylate for Injection …
Phentolamine
A nonselective alpha-adrenergic antagonist. It is used in the treatment of hypertension and hypertensive emergencies, pheochromocytoma, vasospasm of raynaud disease and frostbite, clonidine withdrawal syndrome, impotence, and peripheral vascular disease.
Approved
Matched Salts name: … Phentolamine mesylate …
Matched Products: … Phentolamine Mesylate ... Phentolamine Mesylate Injection Sandoz Standard …
Matched Products: … Phentolamine Mesylate ... Phentolamine Mesylate Injection Sandoz Standard …
Benzatropine
Benztropine, with the chemical formula 3alpha-diphenylmethoxytropane, is a tropane-based dopamine inhibitor used for the symptomatic treatment of Parkinson's disease. It is a combination molecule between a tropane ring, similar to cocaine, and a diphenyl ether from the dialkylpiperazines determined to be a dopamine uptake inhibitor since 1970. The generation of...
Approved
Matched Salts name: … Benzatropine mesylate …
Matched Products: … Benztropine mesylate ... Benztropine Mesylate ... Benztropine Mesylate Injection, USP …
Matched Products: … Benztropine mesylate ... Benztropine Mesylate ... Benztropine Mesylate Injection, USP …
Bromocriptine
Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. It inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia. Bromocriptine is also indicated for the management of signs and symptoms of Parkinsonian Syndrome, as well as the treatment of acromegaly. Bromocriptine has been...
Approved
Investigational
Withdrawn
Matched Description: … Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity ... In 1995, the FDA withdrew the approval of bromocriptine mesylate for the prevention of physiological …
Matched Salts name: … Bromocriptine mesylate …
Matched Products: … Bromocriptine Mesylate ... Bromocriptine mesylate ... BROMOCRIPTINE MESYLATE TABLETS USP …
Matched Salts name: … Bromocriptine mesylate …
Matched Products: … Bromocriptine Mesylate ... Bromocriptine mesylate ... BROMOCRIPTINE MESYLATE TABLETS USP …
Eprosartan
Eprosartan is an angiotensin II receptor antagonist used to treat hypertension. It performs 2 actions on the renin angiotensin system. By preventing the binding of angiotensin II to AT1, vascular smooth muscle relaxes and vasodilation occurs. By inhibiting norepinephrine production, blood pressure is further reduced.
Approved
Matched Salts name: … Eprosartan mesylate ... Eprosartan mesylate dihydrate …
Matched Products: … Eprosartan Mesylate …
Matched Products: … Eprosartan Mesylate …
Imatinib
Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with...
Approved
Matched Salts name: … Imatinib mesylate …
Matched Products: … Imatinib Mesylate ... Imatinib mesylate ... Imatinib mesylate 400 mg …
Matched Products: … Imatinib Mesylate ... Imatinib mesylate ... Imatinib mesylate 400 mg …
Dihydro-alpha-ergocryptine
Alpha-dihydroergocryptine is usually referred to the mixture of the alpha and beta dihydroergocryptine. These two compounds are differentiated in the position of a methyl group. This structural difference is due to a proteinogenic amino acid replacement from leucine to isoleucine. Both compounds are hydrogenated ergot derivatives. Alpha-dihydroergocryptine approved drug product...
Approved
Matched Salts name: … Dihydro-alpha-ergocryptine mesylate …
Ziprasidone
Disorders such as schizophrenia and bipolar disorder can significantly impair mood, cognition, and behavior. These mental illnesses can often be accompanied by comorbidities such as depression and substance abuse, and can significantly impact the quality of life of patients and caregivers. Luckily, several treatment options for psychotic disorders have been...
Approved
Matched Salts name: … Ziprasidone mesylate trihydrate …
Matched Products: … Ziprasidone Mesylate …
Matched Products: … Ziprasidone Mesylate …
Epicriptine
Epicriptine is also known as beta-dihydroergocryptine presents a molecular formula of 9,10 alpha-dihydro-13'-epi-b-ergocryptine. Together with the alpha-dihydroergocryptine, it represents one-third of the ergoloid mesylate mixture. Epicriptine differs from the alpha form on the position of one methyl group. To know more about the mixture please visit DB01049
Approved
Matched Description: … Together with the alpha-dihydroergocryptine, it represents one-third of the ergoloid mesylate mixture …
Busulfan
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought...
Approved
Investigational
Dabrafenib
Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib),...
Approved
Investigational
Matched Description: … Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK …
Matched Salts name: … Dabrafenib mesylate …
Matched Salts name: … Dabrafenib mesylate …
Betahistine
Ménière's disease is a progressive disease of the inner ear characterized by vertigo, tinnitus, and hearing loss. It has a significant impact on both the physical and social functioning of affected individuals.[A220318,L16408]
Betahistine is a histamine-like antivertigo drug used for treating symptoms associated with Ménière's disease. It is thought to...
Approved
Investigational
Matched Salts name: … Betahistine mesylate …
Matched Products: … BETAHISTINE MESYLATE …
Matched Products: … BETAHISTINE MESYLATE …
Sunitinib
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation....
Approved
Investigational
Safinamide
Safinamide is for the treatment of parkinson's disease. It was approved in Europe in February 2015, and in the United States on March 21, 2017.
Approved
Investigational
Matched Salts name: … Safinamide mesylate …
Regorafenib
Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.
Approved
Leuprolide
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to...
Approved
Investigational
Matched Salts name: … Leuprolide mesylate …
Dimetotiazine
Dimetotiazine has considerable antiemetic & serotonin antagonistic action used mainly in allergic skin conditions.
Approved
Matched Salts name: … Fonazine mesylate …
Pefloxacin
A synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria.
Approved
Matched Salts name: … Pefloxacin mesylate ... Pefloxacin mesylate dihydrate …
Lomitapide
Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R).
Approved
Investigational
Matched Salts name: … Lomitapide mesylate …
Dalfopristin
Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. It is not effective against Enterococcus faecalis infections. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome and quinupristin inhibits the late phase of protein synthesis.
Approved
Matched Salts name: … Dalfopristin mesylate …
Osimertinib
Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing...
Approved
Matched Salts name: … Osimertinib mesylate …
Abemaciclib
Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for...
Approved
Investigational
Matched Salts name: … Abemaciclib mesylate …
Trovafloxacin
Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective...
Approved
Investigational
Withdrawn
Matched Salts name: … Trovafloxacin mesylate …
Tropisetron
Tropisetron is an indole derivative with antiemetic activity. As a selective serotonin receptor antagonist, tropisetron competitively blocks the action of serotonin at 5HT3 receptors, resulting in suppression of chemotherapy- and radiotherapy-induced nausea and vomiting.
Tropisetron appears to be well tolerated with the most frequently reported adverse effect being headache. Extrapyramidal...
Approved
Investigational
Matched Salts name: … Tropisetron Mesylate …
Trimipramine
Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties.
Approved
Matched Salts name: … Trimipramine mesylate …
Displaying drugs 1 - 25 of 111 in total